Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a Phase 2a clinical study titled A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). The study aims to assess the change in proteinuria and its impact on the remission rates of nephrotic syndrome in patients with primary FSGS or MCD.
The study tests three experimental drugs: Frexalimab, SAR442970, and Rilzabrutinib, against a placebo. These drugs are designed to treat primary FSGS and MCD by potentially reducing proteinuria and improving remission rates.
This interventional study is randomized with a parallel assignment and quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary aim is treatment-focused.
The study began on December 19, 2024, with an estimated completion timeline of 76 weeks, including a 24-week treatment period and up to 18 visits. The latest update was submitted on June 24, 2025.
The ongoing study could influence Sanofi’s stock performance positively if successful, as it may lead to new treatment options for FSGS and MCD, potentially boosting investor confidence. Competitors in the nephrology treatment space will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.